紫杉醇所致手足综合征的处理。
Management of Paclitaxel-induced hand-foot syndrome.
机构信息
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
出版信息
Breast Care (Basel). 2013 Jun;8(3):215-7. doi: 10.1159/000352097.
BACKGROUND
Hand-foot syndrome (HFS), also known as acral erythema or palmoplantar dysesthesia, is a manifestation of painful erythema and dysesthesia mostly occurring in the palms and soles. Although many chemotherapeutic agents have been shown to cause HFS, it remains an uncommon adverse cutaneous manifestation of paclitaxel.
CASE REPORT
We report a case of paclitaxel-induced grade 3 HFS in a patient with breast cancer. HFS developed after 6 weeks of paclitaxel weekly infusions. The patient was managed by avoidance of sun exposure and extensive use of sunscreen and moisturizers. The skin lesions stabilized and improved gradually. This allowed us to continue the planned necessary course of 12 weeks of paclitaxel under close surveillance.
CONCLUSION
Paclitaxel-induced HFS can be managed with topical creams and avoidance of sun exposure without the need to discontinue chemotherapy. However, close monitoring for any increase or change in symptoms is warranted.
背景
手足综合征（HFS），也称为肢端红斑或掌跖感觉异常，是一种以疼痛性红斑和感觉异常为特征的表现，主要发生于手掌和足底。尽管许多化疗药物已被证明可引起 HFS，但它仍然是紫杉醇少见的皮肤不良反应。
病例报告
我们报告了一例乳腺癌患者使用紫杉醇引起的 3 级 HFS。HFS 在每周紫杉醇输注 6 周后发生。通过避免阳光照射和广泛使用防晒霜和保湿霜来对该患者进行管理。皮肤损伤稳定并逐渐改善。这使我们能够在密切监测下继续进行计划的 12 周紫杉醇治疗。
结论
可以使用局部乳膏和避免阳光照射来管理紫杉醇引起的 HFS，而无需停止化疗。但是，需要密切监测症状是否有任何增加或变化。
Zotero 插件